Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trial
{{output}}
Background: Iberdomide, a cereblon modulator, promotes degradation of transcription factors Ikaros and Aiolos. Objective: Evaluate iberdomide e... ...
